Clinical Trial Search

Primary: Number of Participants Who Died, Experienced Other Serious Adverse Events (SAEs), Adverse Events (AEs) and AEs Leading to Study Drug Discontinuation. — 3; 2; 1; 1…

Primary: Participants With Objective Response — 0; 1; 13 Participants

Primary: Percent of Participants With Major Cytogenetic Response (MCyR) at 6 Months Follow-Up — 51.8; 49.0 percentage of Participants

Primary: Best Response — 20; 3; 3 Participants

Primary: Response Rate — 0; 1; 3; 11 Participants

Primary: Improvement in Quality of Remission: Number of Participants With Response Versus No Response by NCI Working Group Criteria Disease Status Change at Start/End of…

Primary: Response Rate [Complete Remission (CR) +Complete Remission / Incomplete (CRi) + Nodular Partial Remission (nPR) + Partial Remission (PR)] Based on International Workshop…

Primary: Participants With Complete Remission (CR) at 24 Months — 3 Participants

Primary: Number of Patients With Dose-Limiting Toxicities Adverse Events (DLTs) — 0; 0; 0; 0 Participants

Primary: Number of Confirmed Responses (Complete or Partial Response Noted as the Objective Status for a Duration of at Least 2 Months) at 6 Months — 31 Participants

Primary: Number of Participants Who Died and Had Serious Adverse Events (SAEs), Related SAEs, Adverse Events (AEs) Leading to Discontinuation, Related AEs Leading to…

Primary: Progression-free Survival (PFS) — 981.0; 1212.0 Days — p=<.0001

Primary: Overall Objective Response — 10; 5; 26; 4 Participants

Primary: Percent of Participants With Major Hematologic Response (MaHR) With 6 Months of Follow-up From Date of Last Enrollment - Randomized Population — 48.0; 47.9 percentage of…

Primary: Overall Response — 11; 23; 4; 5 participants

Primary: Percentage of Participants With Documented CR, CRi, or PR at the End of Induction Treatment — 82.4 percentage of participants — p=0.0008

Primary: Number of Participants With a Complete Response After Treatment With Fludarabine & Rituximab Followed by Alemtuzumab — 38 participants

Primary: The Number of Participants With In Vitro Dasatinib Sensitivity in Predicting Clinical Activity — 5; 4; 4; 0 Participants — p=0.0106

Primary: Number of Participants With Hematological Response After Three Months of Alemtuzumab — 15 Participants

Primary: Change in Gene Expression Post Chemo — 30; 50 Percent change in cells

Primary: Overall Response Rate — 6; 7 Participants

Primary: Number of Participants With Complete Response (CR) — 14 participants

Primary: Complete Response (CR) — 8.3 Percentage of participants with CR — p=0.014

Primary: Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Discontinuations Due to Adverse Events (AEs) — 3; 6…

Primary: Overall Responders (Complete and Partial Response) — 8; 18 participants

Primary: Number of Patients With Complete Response — 14; 3 participants

Primary: Number of Participants With a Best Response of Either Complete Remission (CR), Nodular Partial Remission (nPR), Complete Remission-incomplete (CRi) or Partial Remission…

Primary: Treatment Success and Feasibility of Autologous Activated T-cells Infusion, Determined by Number of Participants That Achieved Target-Activated T-cell Dose Without DLT…

Primary: Percentage of Participants Achieving Confirmed Complete Response (CR) According to International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 Guidelines in the…

Primary: Percentage of First 25 Enrolled Patients With a Hematologic Response to Ruxolitinib (Complete Response (CR), Partial Response (PR)) — 32; 4 percentage of participants…